🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Prokinetics and Body Surface Gastric Mapping in Dyspeptic Patients: Baseline and Treatment Effects

Recruitingn/aAges 18 Years - anyAllUniversity of Auckland, New Zealand
NCT06854120 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Functional dyspepsia and gastroparesis are common stomach disorders with symptoms like early satiety, nausea, and abdominal pain, and are often evaluated with gastric emptying tests, although the correlation with symptoms is weak. Prokinetic agents (e.g., metoclopramide, erythromycin) and symptom modulators (e.g., nortriptyline, mirtazapine) are commonly used, but selecting the right medication can be difficult, as it's often based on symptoms rather than the underlying gastric issues. Body Surface Gastric Mapping (BSGM) using the Gastric Alimetry device is a novel, non-invasive tool to assess gastric myoelectrical activity and symptoms. This study aims to perform two BSGM recordings-one before and one after medical therapy-to understand how medications affect gastric function and identify baseline BSGM factors that could predict responses to treatment, potentially guiding tailored thera

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients 18 years of age and older * Diagnosis of gastroparesis and/or functional dyspepsia * Being prescribed a prokinetic agent or symptom modulator for their clinical care * Able to undergo BSGM recording both before and during treatment * Able to give informed consent for undergoing a baseline BSGM recording and an additional recording while on treatment Exclusion Criteria: * Under 18 years of age * Prior surgery on esophagus, stomach (appendectomy and cholecystectomy are allowed) * History of skin allergies or a history of extreme sensitivity to cosmetics or lotions * Pregnant women * No vulnerable groups such as prisoners, individuals with known cognitive impairment, or institutionalized individuals be involved
💊

What it tests

  • Gastric Alimetry
📍

Where

3 sites
Temple University
Philadelphia, United States
Western Sydney University
Sydney, Australia
Te Whatu Ora Waitemata
Auckland, New Zealand
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy